http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3858336-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c979a0cca9409172f11f474dabd9f2b1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d33e45e5cbd64b8b893bd62ee22a85b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42f352cc5bd193c17ffff15bf60e16f7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| filingDate | 2020-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3858336-A1 |
| titleOfInvention | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| abstract | The present invention relates to an amorphous solid dispersion comprising ABX464 and at least one pharmaceutically acceptable carrier. The present invention also concerns a pharmaceutical composition comprising said ASD, processes for their preparation, their use as a medicament and more particularly their use in the treatment and/ or prevention of inflammatory diseases, diseases caused by viruses and/or cancer or dysplasia. |
| priorityDate | 2020-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2245.